BALTIMORE--(BUSINESS WIRE)--Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for chronic viral infections announced today that Shawn P. O’Brien, President and Chief Executive Officer, will present a corporate overview at two leading investor conferences; BIO National Venture Conference and the 11th Annual C21 BioVentures.
